Journey Medical (DERM) Long-Term Deferred Tax (2020 - 2021)

Journey Medical (DERM) posted Long-Term Deferred Tax of $8.4 million for Q3 2021, up 475.03% on a QoQ basis from $1.5 million in Q4 2020.

Journey Medical (DERM) Long-Term Deferred Tax (2020 - 2021) Analysis & Trends

Journey Medical's Long-Term Deferred Tax history runs 2 years deep, the most recent figure standing at $8.4 million for Q3 2021.

  • Quarterly Long-Term Deferred Tax changed N/A year-over-year to $8.4 million in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $8.4 million (changed N/A YoY) and the FY2020 annual result came in at $1.5 million, changed N/A from the prior year.
  • Long-Term Deferred Tax was $8.4 million for Q3 2021 at Journey Medical, up from $1.5 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $8.4 million in Q3 2021 and bottomed at $1.5 million in Q4 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Haleon 87.22 Bn 85.35 Bn -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn
10 Journey Medical 179.67 Mn 152.45 Mn 9.70 Mn

Historic Data

Download Data
DateValue
Sep 30, 2021 8.36 Mn
Dec 31, 2020 1.45 Mn